There is also an updated standard indemnity where the study Name has been updated to A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (also known as MVC-101), An EGFR x CD3 Conditional Bispecific Redirected Activation (COBRA) Protein in Patients with Unresectable Locally Advanced or Metastatic Cancer

  • Richardson, Gary (Primary Chief Investigator (PCI))
  • Spence, Anne (Project Manager)

Project: Research

Project Details

Effective start/end date7/12/227/12/24


  • Clinical trial
  • Advanced Solid Tumours
  • antibody cancer therapy